Skip to main content
Premium Trial:

Request an Annual Quote

Aureus Pharma Joins European Biomed Program

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Aureus Pharma said today that it will participate in the Biointelligence R&D Programme, a €118.2 million ($159.8 million) European consortium focused on promoting the use of systemic modeling and simulation tools for biomedical databases.

The Paris-based company said that it could receive an estimated €3.5 million for its participation in the program, under which it will contribute knowledge management and content development.

The Biointelligence R&D Programme is being coordinated by Dassault Systèmes and involves industry participants including Sanofi-Aventis, Ipsen, Servier, Pierre Fabre, Bayer Cropscience, and public research institutes such as Inserm, Inria, Genopole, and other partners.

Aureus said that the program also will enable it to evolve its data models to integrate more complex drug and drug candidate properties, biological protocols, or regulation of physiological responses.

The content Aureus will develop for the program will be focused in areas such as oncology, nuclear receptors, proteases, inhibitors, and life sciences semantics.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.